UroAlert - GU Oncology Weekly

February 26, 2026

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.

Surgical Technique and Perioperative and Postoperative Outcomes for Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Performed with the Hugo RAS Robotic Platform: First Large Case Series by the European Association of Urology Roboti

Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis.

Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma.

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.

PA- versus urologist-performed flexible cystoscopy: A comparative study.

Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.

Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

Does the Urinary Microbiome Reflect the Bladder-Cancer-Associated Microbiome? Characterizing the Microbiome in Urine and Cancer Tissue in Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

The role of the tumor microenvironment in penile carcinoma and emerging therapeutic concepts: A review.

Outcomes of Adjuvant Radiation Therapy in Penile Cancer.

Renal Cancer

BRCA2 and NF2-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.

Immune Checkpoint Inhibitor-Associated Myocarditis With Multisystem Immune Toxicity in Renal Cell Carcinoma.

Metastatic renal cell carcinoma: risk of rapid progression to pathological fractures and factors influencing post-treatment survival - a Swedish Nationwide cohort study.

Three-dimensional Models for Individualized Preoperative Planning of Robot-assisted Partial Nephrectomy in Patients with Horseshoe Kidneys: A European Multicenter Case Series (YAU RCC-UroCCR).

Clear Cell Renal Cell Carcinoma Recurrence Three Decades After Nephrectomy Presenting With New-Onset Diabetes.

Evaluation, Optimization, and Validation of a Multiparametric CT Algorithm for Solid Renal Masses: CT-Score Version 2.0.

HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss.

Leaving the Excision Site Open After Complete Excision of a Large Paracervical Leiomyoma With Fumarate Hydratase (FH)-Deficient Morphology May Decrease the Risk of Developing Renal Cell Carcinoma.

Sutureless robotic-assisted partial nephrectomy: a propensity score-matched analysis (UroCCR N.158).

Prostate Cancer

Real-World Data on Barrigel and SpaceOAR Rectal Spacers in Prostate Cancer Radiation Therapy: A Comparative Analysis.

Differential Response to 177Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Extracellular matrix remodeling as a unique mechanism of expansion of periprostatic adipose tissue: implication for prostate cancer aggressiveness.

Determining Barriers to Dietary Change Among Medically Underserved Men With Prostate Cancer.

The path forward for T cell engagers in patients with prostate cancer.

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.

Association between dose to specific pelvic substructures and urinary and sexual dysfunction following Single-Dose ablative radiotherapy for prostate Cancer: A post hoc analysis from the ABRUPT trial.

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.

The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density.

Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India.

Acquisition, image quality, and PI-RADS agreement of ultrahigh-gradient DWI in prostate 3-T MRI.

Readability of Public-Facing Urologic Oncology Trial Summaries on ClinicalTrials.gov

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

Review of radiopharmaceutical therapy in prostate cancer.

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).

PSMA-PET as an emerging tool for response assessment in metastatic prostate cancer (mPC): revolution and necessary evolution.

AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

SECuRE Trial Update: Another Participant with Undetectable PSA & Negative PSMA PET

Value of a repeat 18F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy.

Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.

Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.

Cancer-Specific Mortality in Rare Histological Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy.

Impact of Pre-treatment Testosterone Levels on Severity of Adverse Effects in Men on Androgen Deprivation Therapy for Prostate Cancer.

Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer.

Physical activity at baseline and risk of prostate cancer grade reclassification on active surveillance: results from a prospective cohort study.

Gut Microbiome as a Lifestyle Risk Factor Associated with Prostate Cancer.

Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.

Ten-Year Experience Transitioning from MRI-guided Transrectal to Transperineal Prostate Biopsies at a Large Single-Institution Academic Center.

Upper Tract Tumors

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab.

Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy.

Artificial Intelligence-Based Personalized Oncological Outcome Prediction Model for Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Development and Multicenter Validation - Beyond the Abstract

Testicular Cancer

International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey.

Mental Health Burden of a Testicular Cancer Diagnosis: Insights from a Large Claims Database.

Patient-Reported Outcomes and Long-Term Toxicity in stage I TGCT: A Retrospective Single-Center Cohort (1994-2023).

Decoding testicular germ cell tumors: integrating risk, biology, and biomarkers into future care.

New Insights into Nectin-4 Expression in Testicular Choriocarcinoma and Its Potential Treatment with Enfortumab Vedotin: Analysis of a Multi-Institutional Series and Association with Clinical-Pathological Features - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC